Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma
Conclusions: These results support use of copanlisib in indolent lymphoma patients with well-controlled diabetes or hypertension. In particular, the transient hyperglycemia in diabetic patients did not exacerbate metabolic status as reflected in HbA1c values. Thus, patients with these pre-existing conditions should not be precluded treatment a priori.DisclosuresZinzani: Celltrion: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees; TG Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees; PFIZER: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Speakers Bureau; Bayer: Membership on an entity's Board of Directors or advisory committees; PFIZER: Honoraria, Membership on an entity's Board of Directors or advisory committees; MSD: Honoraria, Speakers Bureau; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees; Verastem: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Bayer: Membership on an entity's Board of Directors or advisory committees; Merck: Honoraria, Membershi...
Source: Blood - Category: Hematology Authors: Zinzani, P. L., Santoro, A., Mollica, L., Leppa, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., Morschhauser, F., Rodrigues, L., Reeves, J., Hiemeyer, F., Miriyala, A., Garcia-Vargas, J., Childs, B. H., Dreyling, M. H Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Poster I Source Type: research
More News: Arrhythmia | AstraZeneca | Atrial Fibrillation | Diabetes | Diabetes Mellitus | Employment | Endocrinology | Hypertension | Lymphoma | Merck | Non-Hodgkin's Lymphoma | Pfizer | Pharmaceuticals | Rituxan | Study | Toxicology